Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-MDD-2 adjunctive brenipatide relapse-prevention study in adults with major depressive disorder
jRCT2051260167Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of brenipatide in major depressive disorder (MDD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to relapse of major depressive disorder. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
brenipatide
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2051260167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260167.